Clinical Trial Update: De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating de-escalation by discontinuing venetoclax and azacitidine in AML patients who are responding to therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: Institut Paoli-Calmettes | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING